Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27471398)

Published in Onco Targets Ther on July 12, 2016

Authors

Yong-Fa Zhang1, Wei Wei1, Jia-Hong Wang1, Li Xu1, Pei-En Jian1, Cheng-Zuo Xiao2, Xiao-Ping Zhong1, Ming Shi1, Rong-Ping Guo1

Author Affiliations

1: Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou.
2: Department of General Surgery, Shenzhen Shajing Affiliated Hospital of Guangzhou Medical University, Shenzhen, People's Republic of China.

Articles cited by this

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93

Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32

Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg (1990) 3.25

Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol (2014) 2.91

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81

Angiogenesis in liver disease. J Hepatol (2008) 2.31

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10

Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol (2010) 2.00

The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer (1997) 1.86

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist (2012) 1.76

Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65

Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol (2008) 1.61

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 1.52

Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci (2008) 1.44

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology (2013) 1.24

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther (2008) 1.24

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther (2011) 1.21

Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol (2008) 1.19

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist (2010) 1.16

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer (2012) 1.11

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol (2013) 1.11

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis (2013) 1.08

Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. Radiology (2014) 1.08

The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer (2014) 1.04

Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer (2011) 0.95

Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol (2012) 0.94

Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Intervent Radiol (2008) 0.92

Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol (2013) 0.88

TACE and sorafenib: a good marriage? J Clin Oncol (2011) 0.87

Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res (2012) 0.86

Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chin J Cancer (2013) 0.86

Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. Onco Targets Ther (2014) 0.84

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther (2009) 0.82

Treatment outcomes of transcatheter arterial chemoembolization for hepatocellular carcinoma that invades hepatic vein or inferior vena cava. Cardiovasc Intervent Radiol (2014) 0.79

Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. J Gastrointest Cancer (2010) 0.78

Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clin Radiol (2014) 0.78

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Oncol Lett (2014) 0.77